



COPY OF PAPERS  
ORIGINALLY FILED

030639.0027.0111

RECEIVED

JUN 04 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Orville G. Kolterman, et al.

Serial No. 09/889,330

International Application Filing Date: January  
14, 2000

For: **NOVEL EXENDIN AGONIST  
FORMULATIONS AND METHODS  
OF ADMINISTRATION THEREOF**

Group Art Unit: 1614

Examiner: Not yet assigned

TECH CENTER 1600/290

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

**REQUEST TO CORRECT INVENTORSHIP**  
**UNDER 37 C.F.R. §1.48(a)**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is a request for correction of inventorship set forth in the Declaration mailed October 22, 2001. The Declaration should include James J. L'Italien as an inventor, consistent with the inventorship of the International Application from which the subject application was filed under 35 U.S.C. §371. It is respectfully requested that the Patent Office issue a Corrected Filing

**CERTIFICATE OF MAILING**  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

May 17, 2002  
Date of Deposit

BARBARA J. KIELT  
Name of Person Mailing Paper  
Barbara J. Kiel  
Signature of Person Mailing Paper

02 AOSMAN1 00000060 09889330  
130.00 0P

Receipt in which James J. L'Italien is also included as an inventor. In accordance with 37 C.F.R.

§1.48(a), enclosed are the following:

- a. Statement from James J. L'Italien, who is being added as an inventor;
- b. New Declaration, which is executed by all three inventors;
- c. Written consent of Amylin Pharmaceuticals, Inc., the assignee of the two originally named inventors, Andrew Young and Orville Kolterman, which includes the required Statement Under Rule 3.73; and
- d. The fee required under 37 C.F.R. §1.17(i).


Enclosed is a check in the amount of \$130.00 to cover the fees set forth in 37 C.F.R.

1.17(i) required for this request. If the enclosed fee is incorrect, please charge or credit our Deposit Account No. 50-1273 for the appropriate amount.


Respectfully submitted,

Brobeck, Phleger & Harrison LLP

Dated: 5-17-02

By   
Lisa M. McGeehan  
Reg. No. 41,185

Brobeck, Phleger & Harrison LLP  
12390 El Camino Real  
San Diego, CA 92130-2081  
Telephone: (858) 720-2500  
Facsimile: (858) 720-2555



COPY OF PAPERS  
ORIGINALLY FILED

PATENT  
030639.0027.UTL1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Orville G. Kolterman, et al.

Serial No. 09/889,330

International Application Filing Date: January 14,  
2000

For: **NOVEL EXENDIN AGONIST  
FORMULATIONS AND METHODS OF  
ADMINISTRATION THEREOF**

Group Art Unit: 1614

Examiner: Not yet assigned

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

**STATEMENT OF INVENTOR FOR CORRECTION OF INVENTORSHIP**  
**UNDER 37 C.F.R. §1.48(a)**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, **James J. L'Italien**, am an inventor of the above-referenced application. My omission as an inventor in the original Declaration occurred without deceptive intention.



Respectfully submitted,

Dated: 1 May 2002 J. Mahoud 5-1-2002

James J. L'Italien  
James J. L'Italien

**CERTIFICATE OF MAILING**  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 17, 2002  
Date of Deposit

Barbara J. Kelt  
Name of Person Mailing Paper

Barbara J. Kelt  
Signature of Person Mailing Paper



COPY OF PAPERS  
ORIGINALLY FILED

PATENT  
030639.0027.UTL1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900

In re Application of:

Orville G. Kolterman, et al.

Serial No. 09/889,330

International Application Filing Date: January  
14, 2000

For: **NOVEL EXENDIN AGONIST  
FORMULATIONS AND METHODS  
OF ADMINISTRATION THEREOF**

Group Art Unit: 1614

Examiner: Not yet assigned

**STATEMENT OF ASSIGNEE FOR CORRECTION OF INVENTORSHIP**  
**UNDER 37 C.F.R. §1.48(a)**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Amylin Pharmaceuticals, Inc., assignee of the entire right, title, and interests of Andrew Young and Orville Kolterman, the two inventors named in the originally filed Declaration for the subject application, hereby consents to the correction of inventorship set forth in the accompanying papers. Amylin Pharmaceuticals, Inc., hereby certifies that it is the assignee of

**CERTIFICATE OF MAILING**  
**(37 C.F.R. §1.8a)**

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

May 17, 2002  
Date of Deposit

BARBARA J. KIELT  
Name of Person Mailing Paper  
Barbara J. Kielt  
Signature of Person Mailing Paper

these rights by virtue of an assignment from those two inventors to Amylin Pharmaceuticals, Inc., which was mailed to the U.S. Patent and Trademark office with a recordation cover sheet on October 22, 2001. A copy of the executed assignment is submitted herewith.


I have reviewed all documents in the chain of title for the patent application identified above and, to the best of my knowledge and belief, the rights, title, and interests of Andrew Young and Orville Kolterman reside in the assignee identified above.

I am empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like are so made, are punishable by fine or imprisonment, or both, under Section 1001, title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

AMYLIN PHARMACEUTICALS, INC.

Dated: 5-17-02

By:   
Lloyd A. Rowland  
Vice President and General Counsel